Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays

被引：3

作者：

Filella, X

Ballesta, AM

Fox, M

Mitchell, H

Molina, R

Purstner, P

Thome, H

机构：

[1] CHARING CROSS HOSP,DEPT MED ONCOL,LONDON W6 8RF,ENGLAND

[2] UNIV HOSP WOMEN,ENDOCRINOL LAB,GRAZ,AUSTRIA

[3] HOSP CHAMBERY,DEPT BIOCHEM,CHAMBERY,FRANCE

来源：

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS | 1996年 / 11卷 / 01期

关键词：

tumor markers; COBAS CORE;

D O I：

10.1177/172460089601100108

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The aim of our study was to evaluate the clinical usefulness of the tumor markers CEA, CA 125 and PSA using the COBAS CORE system from Roche Diagnostic Systems. Our results demonstrate that determination of these markers on the COBAS CORE immunoassasy analyser provides the performance required for routine use in clinical practice. The results obtained in this clinical trial validate the correlation with disease extension, a characteristic that defines and determines the clinical utility of the tumor markers. We also conclude that learning to operate the COBAS CORE system is simple, as is management of the system through the user-friendly software.

引用

页码：40 / 45

页数：6

共 22 条

[1]

ALCOVER J, 1993, ARCH INT UROL, V65, P491

[2]

ARMBRUSTER DA, 1993, CLIN CHEM, V39, P181

[3]

BALLESTA A, 1993, UPDATING TUMOR MARKE, P75

[4] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].